LSE - Delayed Quote GBp

Venture Life Group plc (VLG.L)

Compare
40.50 -1.00 (-2.41%)
At close: November 15 at 3:54 PM GMT

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in GBp.
NameTitlePayExercisedYear Born
Mr. Jeremy Anthony Philip Randall ACA Co-Founder, CEO & Executive Director 495.99k -- 1964
Mr. Daniel James Wells CFO & Director 344.02k -- 1987
Mr. Lodovico Gianluca Braguti Chief Manufacturing Officer & Executive Director 424.66k -- 1960
Ben Colman Director of Corporate Development -- -- --
Mr. Domenico Barbaro Head of Procurement -- -- --
Mr. Ennio Schiro Head of ESG Strategy -- -- --

Venture Life Group plc

12 The Courtyard
Eastern Road
Bracknell, RG12 2XB
United Kingdom
44 13 4457 8004 https://www.venture-life.com
Full Time Employees:?
165

Description

Venture Life Group plc develops and commercializes healthcare products in the United Kingdom, the Netherlands, China, Germany, Italy, Switzerland, rest of Europe, and internationally. The company offers oral healthcare products, including mouthwash, toothpaste, breath freshening capsules, and dental accessories under UltraDEX and Dentyl Dual Action brands; and proctology products, such as Procto-eze Plus range for treating the discomfort caused by haemorrhoids. It also provides dermatology products comprising Myco Clear, a fungal nail cleanser and solution brand; Rosa calma for normalizing and controlling the signs and symptoms related to rosacea; Bioscalin for the cosmetic treatment and prevention of hair loss, hair thinning, and baldness; and skincare solutions under the brand Lubatti. In addition, the company offers women's healthcare products, including BV treatment gel and pessaries; intimate daily wash and soothing cream; moisture gel and plus pessaries; and thrush cream under Balance Activ brand. Further, it provides glucose management products, such as Lift Glucose shots and tablets for the immediate treatment of hypoglycaemia and preventing hypos, as well as Glucogel for the treatment of hypoglycaemia. Additionally, the company offers ENT care products comprising Earol, for the removal of ear wax; EarolSwim, an invisible ear plugs for protecting the ears from water ingress; Baby Earol, an ear spray for babies; and Sterinase for relieving blocked noses, clearing nasal passages, and preventing the risk of allergic reactions and infections. It also provides oncology support products, such as Pomi-T, used for the management of prostate-specific antigen levels in prostate cancer; Gelclair, a muco-adhesive oral rinse for the treatment of Oral Mucositis; and Xonrid, a hyaluronic acid based topical gel, for the prevention and treatment of Radiation Induced Dermatitis. The company was incorporated in 2005 and is headquartered in Bracknell, the United Kingdom.

Corporate Governance

Venture Life Group plc’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

September 30, 2024 at 7:30 AM UTC

Venture Life Group plc Earnings Date

Recent Events

May 24, 2018 at 12:00 AM UTC

Ex-Dividend Date